AR040955A1 - Analogos de ghrelina - Google Patents

Analogos de ghrelina

Info

Publication number
AR040955A1
AR040955A1 ARP030102647A ARP030102647A AR040955A1 AR 040955 A1 AR040955 A1 AR 040955A1 AR P030102647 A ARP030102647 A AR P030102647A AR P030102647 A ARP030102647 A AR P030102647A AR 040955 A1 AR040955 A1 AR 040955A1
Authority
AR
Argentina
Prior art keywords
aib
acc
deleted
dap
dab
Prior art date
Application number
ARP030102647A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR040955A1 publication Critical patent/AR040955A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente comprende análogos de peptidilo que poseen actividad de Ghrelina agonista o antagonista, junto con usos terapéuticos y no terapéuticos de los mismos. Reivindicación 1: Un compuesto conforme a la fórmula: (R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1, en donde: A1 es Gly, Aib, Ala, beta-Ala, o Acc; A2 es Ser, Aib, Act, Ala, Acc, Abu, Act, Ava, Thr, o Val; A3 es Ser, Ser(C(O)-R4), Asp(O-R8), Asp(NH-R9); Cys(S-R14), Dap(S(O)2-R10), Dab(S(O)2-R11), Glu(O-R6), Glu(NH-R7), Thr, Thr(C(O)-R5), o HN-CH((CH2)n-N(R12R13))-C(O); A4 es Phe, Acc, Aic, Cha, 2Fua, 1Nal, 2Nal, 2Pal, 3Pal, 4Pal, hPhe, (X1, X2, X3, X4, X5)Phe, Taz, 2Thi, 3Thi, Trp, o Tyr; A5 es Leu, Abu, Acc, Aib, Ala, Cha, lle, hLeu, Nle, Nva, Phe, Tle, o Val; A6 es Ser, Abu, Acc, Act, Aib, Ala, Gly, Thr, o Val; A7 es Pro, Dhp, Dmt, 3Hyp, 4Hyp, Inc, Ktp, Oic, Pip, Thz, Tic, o eliminado; A8 es Glu, Acc, Aib, Arg, Asn, Asp, Dab, Dap, Gln, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A9 es His, Apc, Aib, Acc, 2Fua, 2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, (X1, X2, X3, X4, X5-)Phe, o eliminado; A10 es Gln, Acc, Aib, Asn, Asp, Glu, o eliminado; A11 es Arg, Apc, hArg, Dab, Dap, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A12 es Val, Abu, Acc, Aib, Ala, Cha, Nva, Gly, lle, Leu, Nle, Tle, Cha, o eliminado; A13 es Gln, Acc, Aib, Asn, Asp, Glu, o eliminado; A14 es Gln, Acc, Aib, Asn, Asp, Glu, o eliminado; A15 es Arg, hArg, Acc, Aib, Apc, Dab, Dap, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A16 es, Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn, HN-CH((CH2)n-(N(R12R13))-C(O), o eliminado; A17 es Glu, Arg, Asn, Asp, Dab, Dap, Gln, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A18 es Ser, Abu, Acc, Act, Aib, Ala, Thr, Val, o eliminado; A19 es Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A20 es Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A21 es Pro, Dhp, Dmt, Inc, 3Hyp, 4Hyp, Ktp, Oic, Pip, Thz, Tic, o eliminado; A22 es Pro, Dhp, Dmt, 3Hyp, 4Hyp, Inc, Ktp, Oic, Pip, Thz, Tic, o eliminado; A23 es Abu, Acc, Act, Aib, Ala, Apc, Gly, Nva, Val, o eliminado; A24 es Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A25 es Leu, Abu, Acc, Aib, Ala, Cha, lle, hleu, Nle, Nva, Phe, Tle, Val, o eliminado; A26 es Gln, Aib, Asn, Asp, Glu, o eliminado; A27 es Pro, Dhp, Dmt, 3Hyp, 4Hyp, Inc, Ktp, Oic, Pip, Thz, Tic, o eliminado; A28 es Acc, Aib, Apc, Arg, hArg, Dab, Dap, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; R1 es -OH, -NH2, -alcoxi (C1-30), o NH-X6-CH2-Z0, en donde X6 es un alquilo (C1-12), alquenilo (C2-12), y Z0 es -H, -OH, -CO2H o -C(O)-NH2; R2 y R3 son, cada un en forma independiente para cada aparición, H, alquilo (C1-20) o acilo (C1-20); R4, R5, R6, R7, R8, R9 , R10, R11 y R14 son, cada uno en forma independiente para cada aparición, alquilo (C1-40), alquenilo (C2-40), alquilo (C1-40) sustituido, alquenilo (C2-40) sustituido, alquilarilo, alquilarilo sustituido, arilo o arilo sustituido; R12 y R13 son, cada uno en forma independiente para cada aparición, H, alquilo (C1-40), acilo (C1-40), alquilsulfonilo (C1-30) o -C(NH)-NH2, en donde cuando R12 es acilo (C1-40), alquilsulfonilo (C1-30), o -C(NH)-NH2, entonces R13 es H o alquilo (C1-40); n es, en forma independiente para cada aparición 1, 2, , 3, 4, ó 5; X1, X2, X3, X4 y X5 son, cada uno en forma independiente para cada aparición, H, F, Cl, Br, I, alquilo (C1-10), alquilo (C1-10) sustituido, arilo, arilo sustituido, OH, NH2, NO2, o CN; siempre que el péptido contenga por lo menos un aminoácido seleccionado entre los grupos que consiste en: A2 es Aib, Acc, o Act; A3 es Dap(S(O)2-R10), Dab(S(O)2-R11), Glu(NH-Hexil), o Cys(S-Decil); A5 es Abu, Acc, Aib, Ala, Cha, lle, hLeu, Nle, Nva, Phe, Tle, o Val; A6 es Abu, Acc, Act, Aib, Ala, Gly, Thr, o Val; A7 es Dhp, Dmt, 3Hyp, 4Hyp, Inc, Ktp, Oic, Pip, Thz, o Tic; A8 es Acc, Aib, Arg, Asn, Asp, Dab, Dap, Gln, Lys, Orn, o HN-CH((CH2)n-N(R12R13))-C(O); A9 es Aib, Acc, Apc, 2Fua, 2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, o (X1, X2, X3, X4, X5-)Phe; y A10 es Acc, Aib, Asn, Asp, o Glu; y además, siempre que el péptido no sea (Lys8)hGhrelina(1-8)-NH2 o (Arg8)Hgrelina(1-8)-NH2, o una sal farmacéuticamente aceptable de los mismos.
ARP030102647A 2002-07-23 2003-07-23 Analogos de ghrelina AR040955A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39783402P 2002-07-23 2002-07-23
US42748802P 2002-11-19 2002-11-19

Publications (1)

Publication Number Publication Date
AR040955A1 true AR040955A1 (es) 2005-04-27

Family

ID=34278194

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030102647A AR040955A1 (es) 2002-07-23 2003-07-23 Analogos de ghrelina
ARP090103204A AR073099A2 (es) 2002-07-23 2009-08-20 Analogos de ghrelina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP090103204A AR073099A2 (es) 2002-07-23 2009-08-20 Analogos de ghrelina

Country Status (18)

Country Link
US (3) US7589058B2 (es)
EP (2) EP2258381A3 (es)
JP (2) JP2006515271A (es)
KR (1) KR101065471B1 (es)
AR (2) AR040955A1 (es)
AT (1) ATE496940T1 (es)
AU (1) AU2003254119B2 (es)
BR (1) BR0312871A (es)
CA (1) CA2491946C (es)
DE (1) DE60335913D1 (es)
IL (1) IL166170A (es)
MX (1) MXPA05000908A (es)
NO (1) NO334857B1 (es)
PL (1) PL212106B1 (es)
PT (1) PT1578778E (es)
RU (3) RU2315059C2 (es)
TW (1) TWI325003B (es)
WO (1) WO2004009616A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1578778E (pt) 2002-07-23 2011-03-07 Ipsen Pharma Análogos de grelina
CA2566703A1 (en) * 2004-05-11 2005-11-24 Vishwa Deep Dixit Methods of inhibiting proinflammatory cytokine expression using ghrelin
CA2625920C (en) 2005-09-28 2014-12-23 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogs of ghrelin
EP1937262B1 (en) * 2005-09-29 2019-05-08 Ipsen Pharma Composition for use in treating gastrointestinal dysmotility
US8992928B2 (en) * 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
ES2424970T3 (es) 2006-03-10 2013-10-10 Ipsen Pharma Uso de un agonista de la grelina para mejorar los efectos catabólicos del tratamiento con glucocorticoides
WO2007108990A2 (en) * 2006-03-13 2007-09-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
BRPI0717169C1 (pt) 2006-09-27 2012-12-04 Ipsen Pharma Sas análogos de grelina substituìda no n-terminal
WO2008067831A2 (en) * 2006-12-05 2008-06-12 Charite Universitätsmedizin - Berlin Use of ghrelin, an analogue thereof or a pharmaceutically acceptable salt thereof
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US8883721B2 (en) * 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
EP2493910A1 (en) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
EP2582715B1 (en) * 2010-06-16 2018-11-28 The Administrators of the Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
JP2015510505A (ja) * 2012-02-03 2015-04-09 ジーランド ファーマ アクティーゼルスカブ グレリン類似体
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN108029863B (zh) * 2018-01-19 2021-07-27 广州英赛特生物技术有限公司 丁酰甘氨酸及其衍生物在制备动物饲料添加剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8821785D0 (en) * 1988-09-16 1988-10-19 Nycomed As Peptide compounds
US5264565A (en) 1991-01-22 1993-11-23 Affymax Technologies, N.V. Nucleic acid encoding the D2 /Ml chimeric receptor
WO1997005252A2 (en) 1995-07-26 1997-02-13 Nps Pharmaceuticals, Inc. Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
WO1997021730A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
US7368427B1 (en) * 1998-12-07 2008-05-06 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas GLP-1 analogues
DK1795598T3 (da) * 1999-07-23 2010-02-01 Kenji Kangawa Hidtil ukendte peptider
WO2001092292A2 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Ghrelin analogs
AU2001283938A1 (en) * 2000-07-24 2002-02-05 Ardana Bioscience Limited Ghrelin antagonists
WO2002083860A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
PT1578778E (pt) 2002-07-23 2011-03-07 Ipsen Pharma Análogos de grelina

Also Published As

Publication number Publication date
EP2258381A3 (en) 2011-11-02
IL166170A0 (en) 2006-01-15
JP2006515271A (ja) 2006-05-25
WO2004009616A3 (en) 2006-02-09
US9133261B2 (en) 2015-09-15
JP2009161546A (ja) 2009-07-23
RU2005104841A (ru) 2005-09-10
US20050272648A1 (en) 2005-12-08
TW200403253A (en) 2004-03-01
MXPA05000908A (es) 2005-07-22
BR0312871A (pt) 2007-07-10
PL377075A1 (pl) 2006-01-23
EP1578778A2 (en) 2005-09-28
IL166170A (en) 2011-01-31
KR101065471B1 (ko) 2011-09-16
CA2491946A1 (en) 2004-01-29
RU2315059C2 (ru) 2008-01-20
PL212106B1 (pl) 2012-08-31
EP2258381A2 (en) 2010-12-08
EP1578778B1 (en) 2011-01-26
EP1578778A4 (en) 2007-02-28
AU2003254119B2 (en) 2007-11-29
RU2009127162A (ru) 2011-01-20
US7589058B2 (en) 2009-09-15
AR073099A2 (es) 2010-10-13
WO2004009616A2 (en) 2004-01-29
CA2491946C (en) 2013-05-28
NO20050083L (no) 2005-03-23
DE60335913D1 (de) 2011-03-10
AU2003254119A1 (en) 2004-02-09
RU2373220C2 (ru) 2009-11-20
NO334857B1 (no) 2014-06-23
KR20050026503A (ko) 2005-03-15
ATE496940T1 (de) 2011-02-15
US20100069299A1 (en) 2010-03-18
US8633151B2 (en) 2014-01-21
US20140135260A1 (en) 2014-05-15
RU2007124275A (ru) 2009-01-10
PT1578778E (pt) 2011-03-07
TWI325003B (en) 2010-05-21

Similar Documents

Publication Publication Date Title
AR073099A2 (es) Analogos de ghrelina
KR100582510B1 (ko) 엘에이치-알에이치 단백질 효능제 또는 길항제, 이의 용도 및 이를 함유하는 약제학적 조성물
AR061780A1 (es) Analogos de ghrelina sustituidos en el extremo n- terminal
AR019131A1 (es) Analogos de polipeptidos pituitarios que activan la adenilato ciclasa, una composicion farmaceutica que los comprende, y el uso de dichos peptidos para lamanufactura de un medicamento
AR066175A1 (es) Ligandos del receptor de melanocortina de peptidos ciclicos
ES2618315T3 (es) Ligandos del receptor de melanocortina modificados con hidantoína
RU2008104802A (ru) Лиганды рецепторов меланокортинов
AR043688A1 (es) Analogos del peptido yy
CA2097192A1 (en) Bombesin antagonists
TW325478B (en) Polypeptide bombesin antagonists
KR910002900A (ko) 합성 펩티드 및 이를 함유하는 제약학적 조성물
HUP0401536A2 (hu) Peptidek és/vagy proteinek, valamint terápiás és/vagy megelőző gyógyszerkészítmény előállítására történő alkalmazásuk
HUP0105094A2 (hu) IGF-I- és IGF-II-gátló növekedési hormont leadó hormon antagonista analógjai és alkalmazásuk
CA2350914A1 (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
JP3810083B2 (ja) 成長因子の放出を促進し得る２−アルキルトリプトファン含有ペプチド化合物
EP0937101B1 (en) Conformationally constrained lh-rh analogues, their uses and pharmaceutical compositions containing them
Bodansky et al. Hindered amines in peptide synthesis. Synthesis of 7-glycine-oxytocin
ATE92078T1 (de) Pharmakologisch aktive peptide.
ES2361818T3 (es) Análogos de la grelina.
MXPA99004512A (es) Analogos lh-rh conformacionalmente restringidos,sus usos y composiciones farmaceuticas que los contiene
Kitagawa et al. Total solid-phase synthesis of human cholecystokinin (CCK)-39
TH35998A (th) Lh-rh เป็ปไทด์ อะนาล็อก ประโยชน์ของสิ่งเหล่านั้นและองค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วยสิ่งเหล่านั้น

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee